In a phase I trial of ONO-4059 (NCT01659255), a BTK inhibitor that acts by inducing classical apoptosis, the ORR was 35% in ABC-DLBCL patients [96, 193]. Here, BTK is linked to diffuse large B-cell lymphoma.